<DOC>
	<DOCNO>NCT02566265</DOCNO>
	<brief_summary>The investigator ' hypothesis administration Fluzone® High-Dose booster patient monoclonal gammopathy ( irrespective age ) lead seroconversion rate exceed 50 % importantly , reduce influenza-related morbidity , reduce interruption cancer therapy may reduce disease progression end flu season</brief_summary>
	<brief_title>Study High-dose Influenza Vaccine Efficacy Repeated Dosing IN Gammopathy Patients</brief_title>
	<detailed_description>Influenza major cause morbidity US . Patients monoclonal gammopathy know increased risk develop influenza . Furthermore , several medication ( proteasome inhibitor ) , commonly use treat tumor , know increase risk tumor . Seasonal influenza vaccination show reduce influenza related morbidity approve routine prophylaxis US . In 2009 , Fluzone® high- dose vaccine FDA approve 2009 adult age 65 old base data regard high rate seroprotection ( define hemagglutination antibody inhibition ( HAI ) titer 40 high ) . In study , investigator administer Fluzone® High-Dose vaccine plan booster patient monoclonal gammopathy irrespective age versus standard care control group . Primary endpoint composite document influenza infection rate disease progression ( defined International Myeloma Working Group criterion ) end flu season . Based background data , investigator expect high rate success experimental arm . As , investigator power success rate 90 % 70 % experimental control arm , respectively . The investigator also analyze several secondary endpoint include rate influenza related morbidity , analysis humoral cellular immune response vaccine rate disease control ( define lack disease progression standard international myeloma work group criterion ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Understand voluntarily sign informed consent form . Age ≥18 year time signing informed consent form . Diagnosis monoclonal gammopathy : Monoclonal Gammopathy Undetermined Significance ( MGUS ) , asymptomatic / active multiple myeloma , asymptomatic / active Waldenstrӧm Macroglobulinemia ( WM ) . Any serious egg allergy prior serious adverse reaction influenza vaccine . Use influenza vaccine 2015 2016 flu season . Women pregnant plan become pregnant study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>influenza</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>Waldenstrom 's macroglobulinemia</keyword>
</DOC>